Prof. Gilles Edan MD
Chair of the Department of Neurology
University Hospital of Rennes
Rennes | France

Gilles Edan is professor of clinical neurology (PUPH)  at Rennes University Hospital (CHU), titular member of the INRIA/INSERM Empenn research unit, and national coordinator of FCRIN4MS (up to 2024). He is a former president of the French   Neurology Society (2017) and current is vice-president of the European Charcot Foundation. His main clinical and research activities are about multiple sclerosis. In 1997, he opened the first MS cClinic in France, following about 6 000 MS patients with MS from Ouestin   France. He was the medical director of the Neurosciences team of the INSERM clinical investigation center (CICP1414) INSERM from 2005 to 2018. An academic clinical trial of mitoxantrone conducted by Prof. Edan was part one of the two pivotal trials for obtaining FDA market approval by the FDA in 2001 (Edan et al JNNP 1997), and this pivotal trial was also the one used by the French authorities in 2003 for the approval of mitoxantrone (ELSEP) in MS. He was one of the members of the international panel that established the new diagnostic criteria for MS (Mc Donald criteria) in 2001 and 2005. In epidemiology, he also developed the concept of two-stage -disability progression in MS (E Leray, Brain 2010), as well as the notion of using a strong immunosuppressant as an induction therapeutic strategy for aggressive relapsing MS (Edan J et al JNNP 2011, PHRC 2005). For many years, his team in Rennes has been extensively involved in MS research in three fields. Epidemiology: reporting f based on our regional registry (Brittany), reporting the incidence and the history of MS in Brittany from 2000 to -2011 (Yaouanq et al Acta Neurol Scand. 2015, Kerbrat et al Eur J Neurol. 2015), and at the national level, reporting the excess of mortality in a large- scale French observational study and the lower than expected risk of suicide (Leray et al PLoS One 2015, Kalson Ray S, Mult Scler 2017). Therapeutics: demonstrating the efficacy of oral (vs. IV) high-dose methylprednisolone (versus IV) for the treatment of relapses, offering the perspective prospect of an easier way of treating relapses (Le Page et al, Lancet 2015), assessing a new agent for treating aggressive MS in a Phase- II trial of pixantrone (Gonsette R, Mult Scler 2016), looking at the long- term efficacy of interferon-beta at 8 years and at 11 years from in an international Phase- III trial (Edan et al J Neurol Neurosurg Psychiatry 2014, Kappos et al Neurology 2016). Imaging: with special interests in new MRI biomarkers of inflammatory   in the CNS (Maarouf A et al Mult Scler 2016), for spinal cord abnormalities in the early stage of MS (Combès et al Mult Scler 2018, A. Kerbrat, Brain 2020 ), and for the evaluation of MS lesion segmentation (O. Commowick et al Sci Rep. 2018)